Eliason, Laurie

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.

Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., et al. (2024) · Blood

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 79

Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

Delforge, M., Patel, K., Eliason, L., Dhanda, D., Shi, L., Guo, S., Marshall, T. S., Arnulf, B., Cavo, M., Nooka, A., et al. (2024) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 31